Relation between yawning behavior and central serotonergic neuronal system in rats

Naunyn-Schmiedeberg's Archives of Pharmacology
S OkuyamaH Aihara

Abstract

Subcutaneously (s.c.) administered apomorphine (0.0125-0.4 mg/kg) or physostigmine (0.025-0.4 mg/kg) to rats elicited yawning. The dose-response curves were bell-shaped. The peak effects of apomorphine and physostigmine were observed with a dose of 0.1 mg/kg of each drug. Yawning elicited by apomorphine (0.1 mg/kg) or physostigmine (0.1 mg/kg) was reduced by intraperitoneally (i.p.) administered 5-hydroxytryptophan (5-HTP, 50-200 mg/kg, given 30 min before). Yawning elicited by apomorphine but not by physostigmine was enhanced by p-chlorophenylalanine (p-CPA, 25-400 mg/kg i.p., given 24 h before). Apomorphine elicited but not physostigmine-elicited yawning was enhanced by pretreatment with 5,7-dihydroxytryptamine (5,7-DHT, 8 micrograms/rat, given 14 days before into the dorsal raphe). This treatment led to a 35% depletion of serotonin (5-HT) in the striatum. 5-HTP, p-CPA or 5,7-DHT given alone did not elicit yawning. Bilateral, intrastriatal microinjection of apomorphine (1.5-50 micrograms/site) but not physostigmine (5-50 micrograms/site) elicited yawning. The dose-response curve was also bell-shaped. These results indicate that central serotonergic pathways play an important role in modulating drug-elicited yawning in rats.

References

Mar 1, 1989·Pharmacology, Biochemistry, and Behavior·S MatsumotoT Furukawa
Oct 1, 1992·Pharmacology, Biochemistry, and Behavior·R Urbá-HolmgrenA Ugarte
Jun 1, 1993·Journal of Affective Disorders·J P FeighnerG C Dunbar
Sep 1, 1996·General Pharmacology·S OkuyamaK Kamata
Apr 29, 1998·European Journal of Pharmacology·A Argiolas, M R Melis
May 1, 1993·Acta Psychiatrica Scandinavica·G C DunbarW T Smith
Feb 1, 1997·Cephalalgia : an International Journal of Headache·A Panconesi, R Sicuteri
Sep 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·G C DunbarR K Shrivastava

Citations

Jun 1, 1976·The Journal of Pharmacy and Pharmacology·B CostallC J Pycock
Sep 15, 1978·European Journal of Pharmacology·J Davies, P Tongroach
Oct 1, 1977·Pharmacology, Biochemistry, and Behavior·E Mogilnicka, V Klimek
Nov 7, 1975·Science·P M GrovesG V Rebec
Sep 1, 1979·Pharmacology, Biochemistry, and Behavior·R Urbá-HolmgrenR M González
May 19, 1977·Nature·R Urbá-HolmgrenB Holmgren
Mar 1, 1973·European Journal of Pharmacology·B Costall, R J Naylor
Mar 24, 1972·Brain Research·O J Broch, C A Marsden
Dec 1, 1983·Pharmacology, Biochemistry, and Behavior·G SerraG L Gessa
Aug 3, 1984·European Journal of Pharmacology·A J GowerC L Broekkamp
Nov 1, 1981·Pharmacology, Biochemistry, and Behavior·J L Marini

Related Concepts

Biochemical Pathway
Microinjections
Neostriatum
5-Hydroxytryptophan
Serotonin Measurement
August Rats
Serotonin
Lentiform Nucleus Structure
5,7-Dihydroxytryptamine Creatine Sulfate
Fenclonine Hydrobromide

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.